Biomarkers for individualized dosage adjustments in immunosuppressive therapy using calcineurin inhibitors after organ transplantation

被引:29
作者
Fu, Rao [1 ]
Tajima, Soichiro [2 ]
Suetsugu, Kimitaka [1 ,2 ]
Watanabe, Hiroyuki [2 ]
Egashira, Nobuaki [1 ,2 ]
Masuda, Satohiro [1 ,2 ]
机构
[1] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Clin Pharmacol & Biopharmaceut, Fukuoka, Fukuoka 8128582, Japan
[2] Kyushu Univ Hosp, Dept Pharm, Fukuoka, Fukuoka 8128582, Japan
关键词
tacrolimus; cyclosporine A; CYP3A5; CYP2C19; MDR1; NGAL; KIDNEY INJURY MOLECULE-1; GELATINASE-ASSOCIATED LIPOCALIN; SINGLE-NUCLEOTIDE POLYMORPHISMS; ACUTE CELLULAR REJECTION; LONG-TERM OUTCOMES; CYCLOSPORINE-A; GENETIC POLYMORPHISMS; RENAL-TRANSPLANTATION; TACROLIMUS DISPOSITION; INDUCED NEPHROTOXICITY;
D O I
10.1038/s41401-018-0070-2
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Calcineurin inhibitors (CNIs), such as cyclosporine A and tacrolimus, are widely used immunosuppressive agents for the prevention of post-transplantation rejection and have improved 1-year graft survival rates by up to 90%. However, CNIs can induce severe reactions, such as acute or chronic allograft nephropathy, hypertension, and neurotoxicity. Because CNIs have varied bioavailabilities, narrow therapeutic ranges, and individual propensities for toxic effects, therapeutic drug monitoring is necessary for all CNIs. Identifying the genetic polymorphisms in drug-metabolizing enzymes will help to determine personalized dosage regimens for CNIs, as CNIs are substrates for CYP3A5 and P-glycoprotein (P-gp, MDR1). CNIs are often concomitantly administered with voriconazole or proton pump inhibitors (PPIs), giving rise to drug interaction problems. Voriconazole and PPIs can increase the blood concentrations of CNIs, and both are primarily metabolized by CYP2C19. Thus, it is expected that interactions between CNIs and voriconazole or PPI would be affected by CYP2C19 and CYP3A5 polymorphisms. CNI-induced acute kidney injury (AKI) is a serious complication of transplantations. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) are noninvasive urinary biomarkers that are believed to be highly sensitive to CNI-induced AKI. In this article, we review the adverse events and pharmacokinetics of CNIs and the biomarkers related to CNIs, including CYP3A5, CYP2C19, MDR1, NGAL, and KIM-1. We hope that these data will help to identify the optimal biomarkers for monitoring CNI-based immunosuppressive therapy after organ transplantation.
引用
收藏
页码:151 / 159
页数:9
相关论文
共 126 条
[1]   Pharmacokinetics, metabolism and interactions of acid pump inhibitors - Focus on omeprazole, lansoprazole and pantoprazole [J].
Andersson, T .
CLINICAL PHARMACOKINETICS, 1996, 31 (01) :9-28
[2]   Chronic cyclosporine nephrotoxicity [J].
Andoh, TF ;
Bennett, WM .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 1998, 7 (03) :265-270
[3]   CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation [J].
Anglicheau, D ;
Thervet, E ;
Etienne, I ;
De Ligny, BH ;
Le Meur, Y ;
Touchard, G ;
Büchler, M ;
Laurent-Puig, P ;
Tregouet, D ;
Beaune, P ;
Daly, A ;
Legendre, C ;
Marquet, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (05) :422-433
[4]   Immunosuppression Based on Everolimus in Liver Transplant Recipients With Severe Early Post-transplantation Neurotoxicity [J].
Bilbao, I. ;
Dopazo, C. ;
Castells, L. ;
Lazaro, J. ;
Caralt, M. ;
Sapisochin, G. ;
Charco, R. .
TRANSPLANTATION PROCEEDINGS, 2014, 46 (09) :3104-3107
[5]   New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone [J].
Bobadilla, Norma A. ;
Gamba, Gerardo .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2007, 293 (01) :F2-F9
[6]   Neutrophil Gelatinase-Associated Lipocalin as an Early Biomarker of Nephropathy in Diabetic Patients [J].
Bolignano, Davide ;
Lacquaniti, Antonio ;
Coppolino, Giuseppe ;
Donato, Valentina ;
Fazio, Maria Rosaria ;
Nicocia, Giacomo ;
Buemi, Michele .
KIDNEY & BLOOD PRESSURE RESEARCH, 2009, 32 (02) :91-98
[7]   Next-generation biomarkers for detecting kidney toxicity [J].
Bonventre, Joseph V. ;
Vaidya, Vishal S. ;
Schmouder, Robert ;
Feig, Peter ;
Dieterle, Frank .
NATURE BIOTECHNOLOGY, 2010, 28 (05) :436-440
[8]   BIOLOGICAL EFFECTS OF CYCLOSPORIN-A - NEW ANTILYMPHOCYTIC AGENT [J].
BOREL, JF ;
FEURER, C ;
GUBLER, HU ;
STAHELIN, H .
AGENTS AND ACTIONS, 1976, 6 (04) :468-475
[9]   Increased Hospital Stay and Allograft Disfunction in Renal Transplant Recipients with Cyp2c19 AA Variant in SNP rs4244285 [J].
Boso, Virginia ;
Jose Herrero, Maria ;
Bea, Sergio ;
Galiana, Maria ;
Marrero, Patricia ;
Remedios Marques, Maria ;
Hernandez, Julio ;
Sanchez-Plumed, Jaime ;
Luis Poveda, Jose ;
Alino, Salvador F. .
DRUG METABOLISM AND DISPOSITION, 2013, 41 (02) :480-487
[10]   Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are Not Associated With Cyclosporine Pharmacokinetics Nor With Cyclosporine Clinical End Points After Renal Transplantation [J].
Bouamar, Rachida ;
Hesselink, Dennis A. ;
van Schaik, Ron H. N. ;
Weimar, Willem ;
MacPhee, Iain. A. M. ;
de Fijter, Johan W. ;
van Gelder, Teun .
THERAPEUTIC DRUG MONITORING, 2011, 33 (02) :178-184